Story · Medicine & Biotech

Aakash Desai: Phase 2 Results for HB0025 Plus Chemotherapy in First-Line NSCLC

1 outlet · first reported by OncoDaily 2d ago

Coverage, in order

  1. 2d ago
    OncoDaily obscure study randomized trialpeer-reviewed
    Aakash Desai: Phase 2 Results for HB0025 Plus Chemotherapy in First-Line NSCLC

    Aakash Desai, Associate Professor at UAB O’Neal Cancer Center, shared on X: “HB0025 phase 2, JAMA Oncology: PD-L1×VEGF BsAb+chemo, 1L driver-neg NSCLC (n=169) ORR 20 mg/kg: nsq 57.1%, sq 74.2%

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.